Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing
|
|
|
- Whitney Harmon
- 8 years ago
- Views:
Transcription
1 Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie, Université Paris Sud, CHU Bicêtre, On behalf of investigators (RM Savic, A Barrail-Tran, X Duval, G Nembot, X Panhard, D Descamps, B Vrijens, A-M Taburet, C Goujard, F Mentré and the ANRS COPHAR Study Group)
2 Rationale of the study ARVs exposure depends on: Pharmacokinetic parameters of a given drug Treatment adherence Adherence measure Pill count Self questionnaire MEMS -> exact timing of drug intake MEMS+PK-> optimization of drug concentrations and exposure Pharmacokinetics /pharmacogenetics of ATV analysis administered with ritonavir, using adherence rates as measured by MEMS
3 Oral Drug and interpatient variability PHENOTYPE D Dose Absorption Target Metabolism/ Elimination Polymorphism of transporter Polymorphism of target Polymorphism of enzyme (CYP) GENOTYPE
4 Patients and Method (I) Treatment naive HIV-infected patients (N=) for months ARV drugs : Reyataz (Atazanavir) ( mg) /ritonavir ( mg) Truvada (Emtricitabine/Tenofovir) In MEMS-capped bottles Sampling For drug assay Extensive PK at week post treatment initiation Through samples up to the end of study at weeks 8, and DNA for genetics of enzymes and transporters
5 Medication Event Monitoring System MEMS «Medication Event Monitoring System» Dosing Date Dosing Time 8 : : : 8: : N= N= Concentration of ATV and exact timing of drug intake
6 Material and method () ATV and RTV assayed by HPLC Pharmacogenetics study : Allelic discrimination / Taqman - Efflux transporters : MRP (rs77), MRP (rs7), MDR (rs) - Metabolism : CYPA (rs777), UGTA*8 (rs 877) - α Glycoprotein : ORM (A7G)
7 ATAZANAVIR CYPA CYPA*/* CYPA*/* Génotypes Frequencies (%) CYPA*/* Africans Caucasians Americans 8.. UGTA*8 CYPA CYPA UGTA CYPA*/* CYPA*/* Low Bioavaibility (Blanco et al., Pharmacogenetics, ) hepatic uptake: OAT, OATP, NTCP biliary excretion: MDR, BSEP, MRP, BCRP Ho R, Kim RB, Clin Pharm Ther, 7
8 Patients characteristics at baseline and clinical outcome Sex Masculin (N=9) Féminin (N=) Age Minimum = ans Médiane = ans Maximum = ans Mode de contamination Voie sexuelle (N=) Indéterminé (N=) HIV-RNA (cp/ml) Minimum= Médiane= Maximum= 7 Nbre de patients avec CV> = TCD+ (/mm ) Minimum= Médiane= 8 Maximum= patients with CD< = virological failures severe side events 8
9 Results (I) : Pharmacogenetics data Gene (rs number) CYPA (A98G) (rs 777) Genotype Number Phenotype * /* Higher expression * /* 7 Higher expression * /* No expression UGTA * /* Gain of function * /*8 *8 /*8 8 Lost of function MDR (CT) (rs ) CC Lower intracellular concentration CT TT 7 Higher intracellular concentration MRP (AG) (rs7) AA 9 Lower intracellular concentration AG GG Higher intracellular concentration MRP (rs77) (C-T) CC CT Higher Concentration TT ORM (A 7G ) AA AG GG 9
10 Results (II) : Atazanavir concentrations «lag-time»
11 Results (III) : Model selection : Several models investigated Transit compartments selected absorption Ke
12 FINAL MODEL FOR ALL OCCASIONS GOLD STANDARD ANALYSIS*: Parameter Estimate RSE (%) IIV (CV %) RSE (%) IOV (CV %) RSE (%) CL (L/h) <% NA V (L) ka (h-) MTT (h) NN.. *GOLD - standard data (MEMS data corrected for what has been reported RV S (%) 9.. in the patient diary) after that all samples which are unreliable has been excluded. RV, >S (%)..7 7 samples from patients samples excluded
13 Effect of CYPA polymorphism on ATV At least copy CYPA* allele CL/F +% And in ATV concentrations
14 Conclusion Le couplage des MEMS et des caractéristiques PK des ARV apporte une mesure de l exposition thérapeutique «globale», permettant d expliquer la réponse virologique L enregistrement des horaires de prise par les MEMS permet de corriger la variabilité individuelle des mesures de concentration des médicaments, et pourrait faciliter l adaptation des posologies Le MEMS est un nouvel outil, dont la place est à définir pour interpréter les données pharmacologiques dans le suivi des patients, en particulier dans les initiations de traitement (molécules nouvelles) ou les modifications chez les patients en échec
15 Acknowledgements Hopital Bicêtre : Pr C. Goujard Inserm U78 : F.Mentré, G.Nembot, X.Panhard, R. Savic Hopital Bichat : X.Duval (co-ip), D.Descamps Bicêtre : AM.Taburet, A.Barrail-Tran, A. Brunet AARDEX: B.Vrijjens Patients Investigators of clinical centers Pharmacists and pharmacologists BMS and Gilead for providing Reyataz and Truvada ANRS
CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial
CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial Julie Bertrand 1,2, Céline Verstuyft 3,4, Monidarin Chou 5,
HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.
Page 1 HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. This report summarises interaction studies relating
EACS 2013. Dominique Braun Universitätsspital Zürich
EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir
Understanding Pharmacokinetic Variability and Managing Drug Interactions
Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases
Drug-Drug Interactions in the Treatment of Hepatitis C
Drug-Drug Interactions in the Treatment of Hepatitis C Jennifer J. Kiser, PharmD University of Colorado Denver Department of Pharmaceutical Sciences May 11, 2013 Disclosures Jennifer Kiser receives or
Liste d'adresses URL
Liste de sites Internet concernés dans l' étude Le 25/02/2014 Information à propos de contrefacon.fr Le site Internet https://www.contrefacon.fr/ permet de vérifier dans une base de donnée de plus d' 1
5èmes journées du Site ANRS-Cameroun Yaoundé, 3-4 juin 2013 ANRS-12235
èmes journées du Site ANRS-Cameroun Yaoundé, -4 juin 201 ANRS-122 Le sang total séché sur papier filtre, DBS (Dried Blood Spot), est-il utilisable pour le suivi virologique en routine des patients VIH+
Personnalisez votre intérieur avec les revêtements imprimés ALYOS design
Plafond tendu à froid ALYOS technology ALYOS technology vous propose un ensemble de solutions techniques pour vos intérieurs. Spécialiste dans le domaine du plafond tendu, nous avons conçu et développé
The question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
Régression logistique : introduction
Chapitre 16 Introduction à la statistique avec R Régression logistique : introduction Une variable à expliquer binaire Expliquer un risque suicidaire élevé en prison par La durée de la peine L existence
Clinical Implementation of. Pharmacist-Managed Service. Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital
Clinical Implementation of Pharmacogenomics Through a Pharmacist-Managed Service Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital Objectives 1. Describe steps for incorporating pharmacogenomic
Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org
Page 1 of 7 HIV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and HCV Therapy, Washington, April 2014. This report summarises interaction studies relating
When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective
Science at Sunrise, March 7, 2015 When should in vivo transportermediated drug-drug interaction studies be conducted? A scientific perspective Lei Zhang, Ph.D. Office of Clinical Pharmacology Office of
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
Pharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.
A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria
Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc.
Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. CRD Le Virage Équipe TDO GMF de l UMF Charles LeMoyne St-Lambert, Quebec February 2012 Potential Conflicts of Interest
Introduction. GEAL Bibliothèque Java pour écrire des algorithmes évolutionnaires. Objectifs. Simplicité Evolution et coévolution Parallélisme
GEAL 1.2 Generic Evolutionary Algorithm Library http://dpt-info.u-strasbg.fr/~blansche/fr/geal.html 1 /38 Introduction GEAL Bibliothèque Java pour écrire des algorithmes évolutionnaires Objectifs Généricité
Lessons from the Stanford HIV Drug Resistance Database
1 Lessons from the Stanford HIV Drug Resistance Database Bob Shafer, MD Department of Medicine and by Courtesy Pathology (Infectious Diseases) Stanford University Outline 2 Goals and rationale for HIVDB
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
The Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
How To Understand And Manage Asthma In Children
ASTHMA Kaitlin Atkinson Family Resource Library Resource List Follow @CHEOfrl Follow @CHEOhospital General Information and Resources for Parents 100 questions & answers about your child's asthma / Plottel,
«Object-Oriented Multi-Methods in Cecil» Craig Chambers (Cours IFT6310, H08)
«Object-Oriented Multi-Methods in Cecil» Craig Chambers (Cours IFT6310, H08) Mathieu Lemoine 2008/02/25 Craig Chambers : Professeur à l Université de Washington au département de Computer Science and Engineering,
London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
HIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HARVONI safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir
Guidance for Industry
Guidance for Industry Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations DRAFT GUIDANCE This guidance document is being distributed for comment
Account Manager H/F - CDI - France
Account Manager H/F - CDI - France La société Fondée en 2007, Dolead est un acteur majeur et innovant dans l univers de la publicité sur Internet. En 2013, Dolead a réalisé un chiffre d affaires de près
Enterprise Data Center A c h itec tu re Consorzio Operativo Gruppo MPS Case S t u d y : P r o g et t o D i sast er R ec o v er y Milano, 7 Febbraio 2006 1 Il G r u p p o M P S L a B a n c a M o n t e d
Management of HIV and TB Co-infection in South Africa
Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
QUALITY AND SAFETY TESTING
QUALITY AND SAFETY TESTING Large scale of solutions for the identification and rapid detection of micro-organisms. Easier investment in molecular techniques Frédéric BAR, Key Account Manager b2 b3b4 Quality
Introduction au BIM. ESEB 38170 Seyssinet-Pariset Economie de la construction email : contact@eseb.fr
Quel est l objectif? 1 La France n est pas le seul pays impliqué 2 Une démarche obligatoire 3 Une organisation plus efficace 4 Le contexte 5 Risque d erreur INTERVENANTS : - Architecte - Économiste - Contrôleur
Drug drug interaction of new HCV drugs
Drug drug interaction of new HCV drugs Stefano Bonora University of Torino Disposition of old DAAs Drug Dosing regimen CYP P-glycoprotein Non-CYP metabolism Telaprevir Q8h No significant boosting by RTV
AgroMarketDay. Research Application Summary pp: 371-375. Abstract
Fourth RUFORUM Biennial Regional Conference 21-25 July 2014, Maputo, Mozambique 371 Research Application Summary pp: 371-375 AgroMarketDay Katusiime, L. 1 & Omiat, I. 1 1 Kampala, Uganda Corresponding
Spectrométrie d absorption moléculaire UV-visible
Spectrométrie d absorption moléculaire 1 faibles quantités échantillon liquide byfiles.storage.live.com/y1php6mrdyehuw8p4jw0... non destructrice bp0.blogger.com/.../m_7spgk78eu/s400/boum_4.png s'applique
Another way to look at the Project Une autre manière de regarder le projet. Montpellier 23 juin - 4 juillet 2008 Gourlot J.-P.
Another way to look at the Project Une autre manière de regarder le projet Montpellier 23 juin - 4 juillet 2008 Gourlot J.-P. Plan of presentation Plan de présentation Introduction Components C, D The
HIV TREATMENT ADHERENCE
Australian Federation of AIDS Organisations PO Box 51 Newtown NSW 2042 www.afao.org.au July 2009 Information on adherence and hints to help manage your HIV medications HIV TREATMENT ADHERENCE What is adherence?
Helen McIlleron 2, Concepta Merry 1, Pete Smith 2, Gary Maartens 2. Trinity College, Dublin, Ireland. University of Cape Town, South Africa
EDCTP 4th annual forum. Building Bridges for Better Health 22 to 24 October 2007, Ouagadougou, Burkina Faso Determining the optimal doses of antiretroviral and antituberculous medications when used in
M1 UE3 Examen final 2014 / 2015 : China infrastructures strategy
UE3 : Marchés internationaux Amonts M1 UE3 Examen final 2014 / 2015 : China infrastructures strategy Pascal ALBERTINI 14/05/2015 L7N 1 China Infrastructures Strategy Vous, Patrick KRON, Président d Alstom,
REQUEST FORM FORMULAIRE DE REQUÊTE
REQUEST FORM FORMULAIRE DE REQUÊTE ON THE BASIS OF THIS REQUEST FORM, AND PROVIDED THE INTERVENTION IS ELIGIBLE, THE PROJECT MANAGEMENT UNIT WILL DISCUSS WITH YOU THE DRAFTING OF THE TERMS OF REFERENCES
HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016
HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 Daily emtricitabine/tenofovir (Truvada ) is safe and effective for reducing the risk of HIV acquisition in sexually
Treating HIV in children with tuberculosis
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
Clinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
Thursday, February 7, 2013. DOM via PHP
DOM via PHP Plan PHP DOM PHP : Hypertext Preprocessor Langage de script pour création de pages Web dynamiques Un ficher PHP est un ficher HTML avec du code PHP
Clinical Implementation of Psychiatric Pharmacogenomic Testing
Clinical Implementation of Psychiatric Pharmacogenomic Testing David A. Mrazek, M.D., F.R.C.Psych. Mayo Clinic Characterizing and Displaying Genetic Variants for Clinical Action December 2, 2011 Relationships
N.C Talam 1, P. Gatongi 2, J. Rotich 3 ; S. Kimaiyo 4. Abstract
74 FACTORS AFFECTING ANTIRETROVIRAL DRUG ADHERENCE AMONG HIV/AIDS ADULT PATIENTS ATTENDING HIV/AIDS CLINIC AT MOI TEACHING AND REFERRAL HOSPITAL, ELDORET, KENYA. Abstract N.C Talam 1, P. Gatongi 2, J.
Medication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
Troncatures dans les modèles linéaires simples et à effets mixtes sous R
Troncatures dans les modèles linéaires simples et à effets mixtes sous R Lyon, 27 et 28 juin 2013 D.Thiam, J.C Thalabard, G.Nuel Université Paris Descartes MAP5 UMR CNRS 8145 IRD UMR 216 2èmes Rencontres
Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions
AIDS Rev. 2013;15:87 101 Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions Clinical Perspective on Drug Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine Herta
Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants
Dosing Metabolism Clopidogrel (Plavix ) 300mg 600mg loading dose 75 mg daily maintenance dose Prodrug activated by CYP2C19 (major), CYP2B6 & metabolism. CYP2B6. 1 Prasugrel (Effient ) 60mg loading dose
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
Audit de sécurité avec Backtrack 5
Audit de sécurité avec Backtrack 5 DUMITRESCU Andrei EL RAOUSTI Habib Université de Versailles Saint-Quentin-En-Yvelines 24-05-2012 UVSQ - Audit de sécurité avec Backtrack 5 DUMITRESCU Andrei EL RAOUSTI
Bac + 04 Licence en science commerciale, option marketing et communication. Degree in computer science, engineering or equivalent
L un de ces postes vous intéresse? Postulez sur djezzy@talents-network.com Communication Brand senior manager Bac + 04 Licence en science commerciale, option marketing et communication. 05 years minimum
Introduction ToIP/Asterisk Quelques applications Trixbox/FOP Autres distributions Conclusion. Asterisk et la ToIP. Projet tuteuré
Asterisk et la ToIP Projet tuteuré Luis Alonso Domínguez López, Romain Gegout, Quentin Hourlier, Benoit Henryon IUT Charlemagne, Licence ASRALL 2008-2009 31 mars 2009 Asterisk et la ToIP 31 mars 2009 1
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
Benin Business visa Application
Benin Business visa Application Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for your travel: Benin business visa checklist Filled
Viral load testing. medical monitoring: viral load testing: 1
medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the
Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
Travaux publics et Services gouvernementaux Canada. Title - Sujet LEARNING SERVICES. Solicitation No. - N de l'invitation E60ZH-070003
Public Works and Government Canada RETURN BIDS TO: RETOURNER LES SOUMISSIONS À: Bid Receiving - PWGSC / Réception des soumissions - TPSGC 11 Laurier St. / 11, rue Laurier Place du Portage, Phase III Core
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Céline Dartois, Karl Brendel, Emmanuelle Comets, Céline Laffont, Christian Laveille, Brigitte Tranchand,
REQUEST FORM FORMULAIRE DE REQUÊTE
REQUEST FORM FORMULAIRE DE REQUÊTE ON THE BASIS OF THIS REQUEST FORM, AND PROVIDED THE INTERVENTION IS ELIGIBLE, THE PROJECT MANAGEMENT UNIT WILL DISCUSS WITH YOU THE DRAFTING OF THE TERMS OF REFERENCES
Generic antiretrovirals in Europe: a blessing or a curse?
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
Risk Factors for Alcoholism among Taiwanese Aborigines
Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social
Statistiques en grande dimension
Statistiques en grande dimension Christophe Giraud 1,2 et Tristan Mary-Huart 3,4 (1) Université Paris-Sud (2) Ecole Polytechnique (3) AgroParistech (4) INRA - Le Moulon M2 MathSV & Maths Aléa C. Giraud
RLC/MAC Uplink Transfer
FORMATION GPRS - TD SIB RLC/MAC Uplink Transfer Access procedure: one phase access CHANNEL REQUEST One Phase Access IMMEDIATE ASSIGNMENT Request Reference / PDCH description / TBF parameters IMMEDIATE_ASSIGNMENT
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
GSAC CONSIGNE DE NAVIGABILITE définie par la DIRECTION GENERALE DE L AVIATION CIVILE Les examens ou modifications décrits ci-dessous sont impératifs. La non application des exigences contenues dans cette
Transporters in membrane vesicles
Transporters in membrane vesicles LIMO award 2011 for technical excellence NCMLS building Jeroen van den Heuvel Dept Pharmacology & Toxicology Radboud University Nijmegen Medical Centre DNA helix staircase
Getting to Know PrEP (Pre-Exposure Prophylaxis)
(Pre-Exposure Prophylaxis) What is PrEP? Prep stands for Pre-Exposure Prophylaxis: a medication that was recently approved by the FDA for daily use that can help high-risk patients who are HIV negative
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
LUDEP 1.0, un logiciel pour ordinateur personnel qui applique le nouveau modèle pulmonaire de la CIPR*
Radioprotection 1994 Vol. 29, n l, pages 81 à 86 Produits nouveaux LUDEP 1.0, un logiciel pour ordinateur personnel qui applique le nouveau modèle pulmonaire de la CIPR* N.S. JARVIS**, A. BIRCHALL** (Manuscrit
Pr. Vinca RIVIERE, PhD, BCBA-D
4 Rue du Tilleul, 59200 TOURCOING 06.37. 87. 12. 91 vinca.riviere@univ-lille3.fr Pr. Vinca RIVIERE, PhD, BCBA-D Professional Experience September 2012 University of Lille III, France Professor of Universities:
Mitigation Strategies for Reactive Intermediates in
Mitigation Strategies for Reactive Intermediates in Drug Discovery ew Perspectives in DMPK: Informing Drug Discovery Royal Society of Chemistry, London February 10-11, 2014 Thomas A. Baillie School of
The United Nations Convention against Corruption An Overview
The United Nations Convention against Corruption An Overview The United Nations Convention against Corruption Adopted by the General Assembly: Resolution 58/4, 31 October 2003 Entry into Force: 14 December
Expérience appui ANR Zimbabwe (Medicines Control Authority of Zimbabwe -MCAZ) Corinne Pouget -AEDES
Expérience appui ANR Zimbabwe (Medicines Control Authority of Zimbabwe -MCAZ) Corinne Pouget -AEDES 1 Zimbabwe Pharmaceutical Industry The Market Small Country of ca.13 million people Human Pharmaceutical
In-Home Caregivers Teleconference with Canadian Bar Association September 17, 2015
In-Home Caregivers Teleconference with Canadian Bar Association September 17, 2015 QUESTIONS FOR ESDC Temporary Foreign Worker Program -- Mr. Steve WEST *Answers have been updated following the conference
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
Management of Drug-drug Interactions in Hepatitis C Therapy
Management of Drug-drug Interactions in Hepatitis C Therapy David M. Burger Professor of Clinical Pharmacy Radboud University Nijmegen Medical Center The Netherlands IDPharmacology@akf.umcn.nl A case to
TRANSDUCTION DU SIGNAL. Messagers intracellulaires Couplage aux protéines G Transmission via la voie des MAP kinases Transmission via la voie du NO
TRANSDUCTION DU SIGNAL Messagers intracellulaires Couplage aux protéines G Transmission via la voie des MAP kinases Transmission via la voie du NO TRANSDUCTION DU SIGNAL - MESSAGERS INTRACELULAIRES TRANSDUCTION
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department
This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy.
Drug interactions Institute of Tropical Medicine, Antwerpen, October 2007 Learning objectives This lecture offers theoretical and practical information about drug interactions in antiretroviral therapy.
Thailand Business visa Application for citizens of Hong Kong living in Manitoba
Thailand Business visa Application for citizens of Hong Kong living in Manitoba Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for
Drug-Drug Interactions
Slide 1 Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool C-Hep Berlin October 2012 Interactions with the new HepC drugs are challenging! Slide 2 Number of
Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions
Molecular Pathology : Principles in Clinical Practice Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions KT Jerry Yeo, Ph.D. University of Chicago Email: jyeo@bsd.uchicago.edu
Travaux publics et Services gouvernementaux Canada. Title - Sujet INFRASTRUCTURE MANAGEMENT SERVICES. Solicitation No. - N de l'invitation
Public Works and Government Services Canada RETURN BIDS TO: RETOURNER LES SOUMISSIONS À: Bid Receiving - PWGSC / Récption des soumissions - TPSGC 11 Laurier St./11, rue Laurier Place du Portage, Phase
Outsourcing in Drug Development From the Bench to the Market. Steven A. Kates, PhD Ischemix LLC
Outsourcing in Drug Development From the Bench to the Market Steven A. Kates, PhD Ischemix LLC Ischemix LLC 2012 Introduction Drug Development Process Ischemix LLC 2012 2 Introduction Drug Development
Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD
Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can
Pig skin as an alternative to human skin for skin metabolism studies?
Pig skin as an alternative to human skin for skin metabolism studies? H. Osman-Ponchet, A. Lemoine, A. Gaborit, K. Sevin, M. Alriquet, P. Comby, B. Ruty 2 nd Skin Metabolism Meeting October 10-11, 2013
Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency
Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Routine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
HIV 1. A reference guide for prescription HIV-1 medications
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin
PAGE 2015, Crete PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin What is the optimal testosterone level? Nelleke Snelder,